The total return over the past 12 months is +46.93% vs. +16.94% for the S&P 500. So far it's up -3.04% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +46.93% | +38.00% | +41.40% | +35.76% | N/A | N/A |
| Total Return CAGR | +46.93% | +38.00% | +41.40% | +35.76% | N/A | N/A |
| Revenue CAGR | +56.87% | +62.03% | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Axsome Therapeutics, Inc. (AXSM)
| Year | Start price | End price | AXSM Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $182.64 | $177.08 | (3.04%) | +14.51% | (17.55%) |
| 2025 | $84.61 | $182.64 | +115.86% | +17.72% | +98.14% |
| 2024 | $79.59 | $84.61 | +6.31% | +24.89% | (18.58%) |
| 2023 | $77.13 | $79.59 | +3.19% | +26.19% | (23.00%) |
| 2022 | $37.78 | $77.13 | +104.16% | (18.17%) | +122.33% |
| 2021 | $81.47 | $37.78 | (53.63%) | +28.74% | (82.37%) |
| 2020 | $103.36 | $81.47 | (21.18%) | +18.37% | (39.55%) |
| 2019 | $2.82 | $103.36 | +3565.25% | +31.22% | +3534.03% |
| 2018 | $5.60 | $2.82 | (49.64%) | (4.56%) | (45.08%) |
| 2017 | $6.75 | $5.60 | (17.04%) | +21.70% | (38.74%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
